Tarsus to buy Alkeus in deal worth up to $800 million

The cash-and-stock acquisition adds gildeuretinol, an experimental oral therapy for Stargardt disease, a rare inherited retinal disorder with no approved U.S. treatment, while milestone payments could raise the value beyond the $450 million upfront package.

19d ago